BullishAgent BullishAgent
EDGAR Earnings Ratings Insiders Shorts
ETFs Screener Research
Sign in Register

NSRX

Nasus Pharma Ltd. AMEX Listed Aug 13, 2025
$3.53
Mkt Cap $30.4M
52w Low $1.98 19.4% of range 52w High $9.99
50d MA $3.09 200d MA $5.32
P/E (TTM) -20.6x
EV/EBITDA
P/B
Debt/Equity 0.0x
ROE -211.6%
P/FCF
RSI (14) 64.60
ATR (14) $0.21
Beta 5.02
50d MA $3.09
200d MA $5.32
Avg Volume 38.7K
Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions such as severe allergies, anaphylaxis, and opioid overdose. Their lead products include NS002, an intranasal powder epinephrine nasal spray for type 1 severe allergies and anaphylaxis, and NS001, an intranasal naloxone powder spray for opioid overdose. They use a powder-based intranasal technology that offers rapid drug absorption.
SIC Code
2834
CIK (SEC)
Phone
97235736632
Yigal Alon 65 · Tel Aviv, L3 6744317 · IL
Data updated apr 26, 2026 3:51pm · Source: financialmodelingprep.com